Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

560.36 -4.27 (-0.76%)
Streaming Delayed Price Updated: 2:33 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 884,194
Open 551.50
Bid (Size) 559.91 (1)
Ask (Size) 560.86 (1)
Prev. Close 564.63
Today's Range 541.00 - 561.31
52wk Range 476.49 - 1,024.36
Shares Outstanding 91,779,465
Dividend Yield 0.31%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Are Regeneron And Scholar Rock Shares Falling On Monday?
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk. 
Via Stocktwits
Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss
Regeneron gene therapy for OTOF-related hearing loss shows rapid, sustained improvements, including normal hearing in some participants. 
Via Benzinga

Performance

YTD
-21.6%
-21.6%
1 Month
+0.1%
+0.1%
3 Month
-1.8%
-1.8%
6 Month
-1.9%
-1.9%
1 Year
-44.8%
-44.8%

More News

Read More
Gapping S&P500 stocks in Monday's session
Via Chartmill
Why Regeneron Pharmaceuticals’ Stock Is Climbing Premarket Today
Via Stocktwits
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Forecasting The Future: 9 Analyst Projections For Regeneron Pharmaceuticals
Via Benzinga
Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients
Via Benzinga
Investors Brace for Pullback as Short-Bias ETF Inflows Signal Growing Bearishness
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out
Via Investor's Business Daily
Retail Buzz Builds Around Regeneron After FDA Clears Libtayo For High-Risk Skin Cancer; Traders Eye ‘Buying Opportunity’
Via Stocktwits
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September
Via The Motley Fool
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings
Via Benzinga
Wednesday's session: top gainers and losers in the S&P500 index
Via Chartmill
Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday?
Via Benzinga
Which S&P500 stocks are moving on Wednesday?
Via Chartmill
Nvidia, Amphenol, Lockheed Martin And A Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Topics Artificial Intelligence
Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Artificial Intelligence
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Beaten-Down Stocks to Buy and Hold for a Decade
Via The Motley Fool
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Via MarketMinute
1 Healthcare Stock with Exciting Potential and 2 We Ignore
Via StockStory
Topics Stocks
FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder
Via Benzinga
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Why Regeneron (REGN) Shares Are Falling Today
Via StockStory

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 560.36
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 10/13/25 02:33 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 51.43B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 51B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.